Bayer gets US FDA nod for KERENDIA (finerenone) to treat CKD associated with type 2 diabetes
It is a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained eGFR…
Recover your password.
A password will be e-mailed to you.